Enliven Therapeutics's total assets for Q2 2024 were $327.04M, a decrease of -4.59% from the previous quarter. ELVN total liabilities were $22.11M for the fiscal quarter, a -11.79% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.